Osteoporosis
Conference Coverage
Denosumab better at building bone than zoledronic acid
Denosumab appears to be preferable to zoledronic acid when transitioning from oral bisphosphonates in previously treated postmenopausal women.
Conference Coverage
Progress in treating diabetic foot osteomyelitis
News
FDA issues revised warning for adverse effects associated with canagliflozin
The FDA has issued a revised warning and precaution regarding the risk of bone fractures while taking canagliflozin for management of type 2...
News
Osteoporosis trends collide for Mexican American women
Women aged 65 years and older were 4.4 times as likely as men their age to have osteoporosis, and Mexican Americans aged 65 years and older were 2...
News
HLA-matched sibling transplants provide best outcomes in infantile osteopetrosis
News
MDD tied to lower bone mineral density in men
Antidepressant use is associated with lower bone mineral density, but only among men with low body weight.
Conference Coverage
ASCO: Adjuvant denosumab halves fracture risk for breast cancer patients on AIs
Key clinical point: Denosumab reduces the risk of clinical fractures in postmenopausal women taking AIs for early breast cancer. Major finding:...
Conference Coverage
AACE: Bisphosphonates do not prevent fractures in adults with osteogenesis imperfecta
Expect a response to bisphosphonate in maybe two-thirds of OI children.
News
Subclinical hyperthyroidism linked to higher fracture risk
People with subclinical hyperthyroidism have a 36% increased risk for hip fractures.
News
DXA screening: You’re doing it wrong
DXA is underused in women who meet the U.S. Preventive Services Task Force criteria for osteoporosis screening and overused in women who do not....
Conference Coverage
OARSI: Bisphosphonate users less likely to undergo knee replacement
Key clinical point: Bisphosphonate use by women with knee arthritis was associated with a reduced rate of knee surgery. Major finding: Women who...